The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | MRD negativity rates in t(11;14) R/R multiple myeloma following treatment with VenDd or DVd
Jonathan Kaufman, MD, Emory University School of Medicine, Atlanta, GA, provides an overview of updated analyses from a Phase I/II trial of venetoclax + daratumumab + dexamethasone (VenDd) versus bortezomib plus daratumumab and dexamethasone (DVd) in patients with t(11;14)-positive relapsed/refractory (R/R) multiple myeloma (MM). The survival outcome findings have previously been reported, and at ASH 2023, the measurable residual disease (MRD) data were presented. Treatment with the VenDd regimen resulted in a higher rate of MRD negativity, with a tolerable safety profile. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Incyte, BMS, Sanofi
